A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)
Recruiting now · Phase 2 · Has a placebo group
Conditions studied: Obesity, Muscle Loss
In brief
Semaglutide is approved for weight management (weight loss and weight maintenance) in adult obese patients. Drug treatments like semaglutide that result in weight-loss can also decrease muscle mass. The purpose of this study is to investigate the effect of ACM-001.1 (the study drug) on how much muscle is lost when a person takes it with semaglutide (PROACT 1) and how much muscle mass is gained when a person continues taking ACM-001.1 but stops taking semaglutide (PROACT 2).
Key facts
- Study ID
- NCT07101939
- Run by
- Actimed Therapeutics Ltd
- People needed
- 120
- Starts
- 2025-06-23
- Expected to finish
- 2027-03-01
- Last updated by the study team
- 2026-02-17
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Clinical Hospital Center 'Dr Dragisa Misovic - Dedinje' — Belgrade, Serbia (enrolling)
- Clinical Hospital Center Bezanijska kosa — Belgrade, Serbia (enrolling)
- University Clinical Center of Serbia — Belgrade, Serbia (enrolling)
- University Clinical Center Kragujevac — Kragujevac, Serbia (enrolling)
- Klinika Za Endocrinologiju, Dijabetes I Bolesti Metabolizma — Niš, Serbia (enrolling)
- University Clinical Center of Vojvodina — Novi Sad, Serbia (enrolling)
- Opsta bolnica Pancevo — Pančevo, Serbia (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.